Non-transferrin bound iron in Thalassemia: Differential detection of redox active forms in children and older patients

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 55-61

  Breuer, William ^a   Ghoti, Hussam ^b,c   Shattat, Ahmmad ^c   Goldfarb, Ada ^a   Koren, Ariel ^d   Levin, Carina ^d   Rachmilewitz, Eliezer ^b   Cabantchik, Z Ioav ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c Palestinian Authority   (Israel)

^d HAEMEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CITRIC ACID; DEFERASIROX; DEFERIOXAMINE; DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT; LABILE PLASMA IRON; NITRILOTRIACETIC ACID; NON TRANSFERRIN BOUND IRON; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; UNCLASSIFIED DRUG; URIC ACID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BETA THALASSEMIA; BINDING AFFINITY; BINDING ASSAY; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; DIRECTLY CHELATABLE IRON ASSAY; FLUORESCENCE; HUMAN; HUMAN TISSUE; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; ISRAEL; LABILE PLASMA IRON ASSAY; MAJOR CLINICAL STUDY; OXIDATION REDUCTION STATE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; CHELATING AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; IRON; MIDDLE AGED; NITRILOTRIACETIC ACID; OXIDATION-REDUCTION; PROTEIN BINDING; THALASSEMIA; TRANSFERRIN; YOUNG ADULT;

EID: 84155180765     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22203     Document Type: Article

References (33)

1. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277-287.
2. Hider RC, Silva AM, Podinovskaia M, Ma Y. Monitoring the efficiency of iron chelation therapy: The potential of nontransferrin-bound iron. Ann NY Acad Sci 2010; 1202: 94-99.
3. Graham G, Bates GW, Rachmilewitz EA, Hershko C. Nonspecific serum iron in thalassemia: Quantitation and chemical reactivity. Am J Hematol 1979; 6: 207-217.
4. Porter JB. Pathophysiology of transfusional iron overload: Contrasting patterns in thalassemia major and sickle cell disease Hemoglobin 2009; 33: S37-S45.
5. Bradley SJ, Gosriwitana I, Srichairatanakool S, et al. Non-transferrin-bound iron induced by myeloablative chemotherapy. Brit J Haematol 1997; 99: 337-343.
6. Gosriwatana I, Loreal O, Lu S, et al. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 1999; 273: 212-220.
7. Le Lan C, Loréal O, Cohen T, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005; 105: 4527-4531.
8. Pootrakul P, Breuer W, Sametband M, et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron overloaded beta-thalassaemia/HbE patients treated with an oral chelator. Blood 2004; 104; 1504-1510.
9. Evans RW, Rafique R, Zarea A, et al. Nature of non-transferrin-bound iron: Studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem 2008; 13: 57-74.
10. Silva AM, Hider RC. Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron implications for non-transferrin-bound iron speciation. Biochim Biophys Acta 2009; 1794: 1449-1458.
11. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40: 255-263.
12. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23: 185-191.
13. Jacobs EM, Hendriks JC, van Tits BL, et al. Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Anal Biochem 2005; 341: 241-250.
14. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin-bound iron. Anal Biochem 1990; 186: 320-323.
15. Kolb, AM, Smit NP, Lentz-Ljuboje R, et al. Non-transferrin bound iron measurement is influenced by chelator concentration Anal Biochem 2009; 385: 13-19.
16. Breuer W, Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 2001; 299: 194-202.
17. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood 2003; 102: 2670-2677.
18. Zanninelli G, Breuer W, Cabantchik ZI. Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. Brit J Haematol 2009; 147: 744-751.
19. Breuer W, Ermers MJ, Pootrakul P, et al. Deferrioxamine-chelatable iron a component of serum non-transferrin-bound iron used for assessing chelation therapy. Blood 2001; 97: 792-798.
20. Evans PJ, Halliwell B. Measurement of iron and copper in biological systems: Bleomycin and copper-phenanthroline assays. Meth Enzymol 1994; 233: 82-89.
21. Hershko C, Konijn AM, Nick HP, et al. ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001; 97: 1115-1122.
22. Link G, Konijn AM, Breuer W, et al. Exploring the "iron shuttle" hypothesis in chelation therapy: Effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138: 130-138.
23. Link G, Ponka P, Konijn AM, et al. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood 2003; 101: 4172-4179.
24. Burkitt MJ, Gilbert BC. Model studies of the iron-catalysed Haber-Weiss cycle and the ascorbate-driven Fenton reaction. Free Rad Res Commun 1990; 10: 265-280.
25. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858-6862.
26. Roche M, Rondeau P, Singh NR, et al. The antioxidant properties of serum albumin FEBS Lett 2008; 582: 1783-1787.
27. Pollack S, Vanderhoff G, Lasky F. Iron removal from transferrin. An experimental study. Biochim Biophys Acta 1977; 497: 481-487.
28. Birkett DJ, Myers SP, Sudlow G. The fatty acid content and drug binding characteristics of commercial albumin preparations. Clin Chim Acta 1978; 85: 253-258.
29. Evans P, Kayyali R, Hider RC, et al. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl Res 2010; 156: 55-67.
30. Piga A, Longo F, Duca L, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009; 84: 29-33.
31. Glickstein H, Ben-El R, Link G, et al. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood 2006; 108: 3195-3203.
32. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox a once-daily oral iron chelator in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol 2009; 82: 454-457.
33. Greenberg PL, Koller CA, Cabantchik ZI, et al. Prospective assessment of effects on iron overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 2010; 34: 1560-1565.